Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05558904 · ClinicalTrials.gov registry record · Phase 1

An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer

A Phase 1 study of Lung Adenocarcinoma, sponsored by Jonsson Comprehensive Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
60
Enrollment target
1
Study location

NCT05558904 is a Phase 1 study of Lung Adenocarcinoma that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 60 participants, below the 554-participant average among 14 other Lung Adenocarcinoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05558904, a Phase 1 study of Lung Adenocarcinoma, is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The phase I/II trial assess the safety and efficacy of a new positron emission tomography (PET) test for early diagnosis of lung cancer. This study uses PET and Me-4FDG new glucose tracer (alpha-methyl-4-deoxy-4-\[(18)F\]fluoro-D-glucopyranoside) designed specifically to determine glucose update into cells in the body. PET is a non-invasive imaging method used to detect cancer in patient. Me4FDG is a radioactive glucose tracer used in PET to locate cells in the body taking up glucose by SGLT2. SLGT2 is a sodium glucose transport protein that accumulates glucose in some cells, e.g. kidney cells and tumors. This study may help researcher determine how effective PET with ME4FDG tracer works in detecting lung cancer.

Conditions Studied

Lung Adenocarcinoma

Interventions

  • PROCEDURE Computed Tomography
  • PROCEDURE Positron Emission Tomography
  • OTHER Laboratory Biomarker Analysis
  • DRUG Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside

Study Locations (1)

California

  • Yesenia Calzada - Los Angeles

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2023-01-19
Est. Completion 2027-10-01
Phase Phase 1

Sponsor

Jonsson Comprehensive Cancer Center

321 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05558904

The ClinicalTrials.gov registry entry for NCT05558904 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 554-participant average among 14 other Lung Adenocarcinoma trials with a reported enrollment target (89% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Computed Tomography is the first listed.

NCT05558904 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05558904 about?

NCT05558904 is a clinical study titled "An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer". The phase I/II trial assess the safety and efficacy of a new positron emission tomography (PET) test for early diagnosis of lung cancer. This study uses PET and Me-4FDG new glucose tracer (alpha-methyl-4-deoxy-4-\[(18)F\]fluoro-D-glucopyranoside) designed specifically to determine glucose update int...

What is the current status of trial NCT05558904?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2023-01-19. Estimated completion is 2027-10-01.

What conditions does trial NCT05558904 study?

This clinical trial studies the following conditions: Lung Adenocarcinoma.

What interventions are being tested in trial NCT05558904?

The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside (DRUG).

Who is sponsoring clinical trial NCT05558904?

This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05558904 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Adenocarcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.